ISRCTN27178415
Completed
N/A
Clinical investigation into efficacy, haemodynamics and tolerability of simvastatin versus placebo in patients with pulmonary arterial hypertensio
niversity Hospital Giessen (Germany)0 sites40 target enrollmentJune 14, 2006
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Pulmonary hypertension
- Sponsor
- niversity Hospital Giessen (Germany)
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Female and male patients of any racial origin with pulmonary hypertension (PH)
- •2\. Having fulfilled his/her 18th birthday on day 1 of the study
- •3\. Modified New York Heart Association (NYHA) class II or III
- •4\. PH due to idiopathic pulmonary arterial hypertension or collagen vascular disease associated PH
- •5\. Cardiac catheterisation within the last year consistent with PH, specifically pulmonary artery mean pressure (PAPM) greater than or equal to 25 mmHg (at rest), pulmonary capillary wedge pressure (PCWP) (or left ventricular \[LV] end diastolic pressure) less than or equal to 15 mmHg, and peripheral vascular resistance (PVR) greater than 3 mmHg/l/min
- •6\. Echocardiogram on day 1 consistent with PH, more specifically, evidence of right ventricular hypertrophy or dilation, evidence of normal left ventricular function, and absence of mitral valve stenosis
- •7\. Six\-minute walk test between 150 and 450 m
- •8\. Patients receiving conventional PH therapy. Stable for one month.
- •9\. Able to understand and willing to sign the informed consent form
- •10\. Negative pregnancy test (ß\-human chorionic gonadotropin \[HCG]) at the start of the trial and appropriate contraception throughout the study for women of child\-bearing potential
Exclusion Criteria
- •1\. Pregnancy and/or lactation
- •2\. PH of any cause other than permitted in the entry criteria
- •3\. Contraindication for cardiac magnetic resonance (CMR) scan or heart catheterisation
- •4\. Any change in disease\-targeted therapy within the last four weeks
- •5\. Patients requiring prostanoid therapy at the start of the study
- •6\. Patients already taking a statin
- •7\. Any subject who has received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study
- •8\. Known intolerance to hydroxy\-methylglutaryl coenzyme A (HMG\-CoA)\-inhibitors (statins) or any of the excipients
- •9\. Active liver disease, porphyria or elevations of serums transaminases greater than three times upper limit of normal (ULN) or bilirubin greater than 1\.5 x ULN
- •10\. Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, human immunodeficiency virus \[HIV] protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone, ciclosporin and danazole)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension(Shorttitle: SIPHT)Double-blind, randomized, prospective Phase III-b study for 6 months with adjusting doses of simvastatin (40/80 mg daily) or placebo followed by an open-label period with a final dose of simvastatin 80 mg daily for another 6 months - SIPHTModified NYHA class II or III patients with Pulmonary Hypertension (PH), ICD: 416.9MedDRA version: 8.1Level: LLTClassification code 10020787Term: Hypertension pulmonaryEUCTR2005-004863-41-DEDept. of Internal Medicine II, University Hospital Giessen40
Completed
N/A
Compare in Blood pressure and pulse rate in heart surgery patients using two drugsCTRI/2019/02/017839Sri Ramakrishna hospital60
Not Yet Recruiting
Phase 2
Comparision of effect of cisatracurium and vecuronium (both muscle relaxant) in a patient undergoing laproscopic appendicectomyCTRI/2019/05/019453Government medical college Bhavnagar
Completed
N/A
Haemodynamic performance and clinical outcome following aortic valve replacementCardiovascular surgerySurgeryOther and unspecified disorders of circulatory systemISRCTN78125390Department of Health
Not Yet Recruiting
N/A
Evaluation of all haemodnamic changes occuring during total knee arthroplasty under regional aanesthesiaHealth Condition 1: M171- Unilateral primary osteoarthritisof kneeCTRI/2020/05/025111Department of anaesthesia